Jason Segal

The market makes noise. I tell the story. ASX life sciences companies explained.

The Pulse Check

Mar 18, 2026

•

3 min read

Flash update on my day trip to Brisbane

Jason Segal

The Pulse Check

Medical Device Playbook: From FDA Clearance to Commercial Success

Mar 17, 2026

•

16 min read

Medical Device Playbook: From FDA Clearance to Commercial Success

Jason Segal

The Pulse Check

First pick flying, plus my plans for the Armchair Portfolio

Mar 16, 2026

•

7 min read

First pick flying, plus my plans for the Armchair Portfolio

Jason Segal

The Pulse Check

My First Armchair Pick: Tetratherix (ASX: TTX)

Mar 16, 2026

•

24 min read

My First Armchair Pick: Tetratherix (ASX: TTX)

Jason Segal

The Pulse Check

Mar 13, 2026

•

4 min read

The Curse of the Friday the 13th

Jason Segal

The Pulse Check

Mar 12, 2026

•

5 min read

A Nervous Wait for the Immutep Results

Jason Segal

The Pulse Check

Boom or Bust: The Immutep (ASX: IMM) Trade

Mar 11, 2026

•

10 min read

Boom or Bust: The Immutep (ASX: IMM) Trade

Jason Segal

The Pulse Check

Bloodbath Yesterday. Bounce Today? The Market Seasaw

Mar 10, 2026

•

9 min read

Bloodbath Yesterday. Bounce Today? The Market Seasaw

Jason Segal

The Pulse Check

Trust Your Gut: The Microba (ASX: MAP) Story

Mar 6, 2026

•

13 min read

Trust Your Gut: The Microba (ASX: MAP) Story

Jason Segal

The Pulse Check

The M&A Slide Just Updated Itself: $1.5 billion deal

Mar 5, 2026

•

5 min read

The M&A Slide Just Updated Itself: $1.5 billion deal

Jason Segal

The Pulse Check

Three Shots, One Strategy: The Syntara (ASX: SNT) Story

Mar 4, 2026

•

12 min read

Three Shots, One Strategy: The Syntara (ASX: SNT) Story

Jason Segal

The Pulse Check

Risk On, Risk Off: Understanding the Market’s Rhythm

Mar 2, 2026

•

6 min read

Risk On, Risk Off: Understanding the Market’s Rhythm

Jason Segal

The Pulse Check

A US-First Strategy for Ovarian Cancer Screening: The Cleo (ASX: COV) story

Feb 27, 2026

•

14 min read

A US-First Strategy for Ovarian Cancer Screening: The Cleo (ASX: COV) story

Jason Segal

The Pulse Check

Feb 26, 2026

•

7 min read

Half-Yearlys are out. Score Check?

Jason Segal

The Pulse Check

Climbing the Diagnostics Mount Everest: The BCAL (ASX: BDX) Story

Feb 25, 2026

•

17 min read

Climbing the Diagnostics Mount Everest: The BCAL (ASX: BDX) Story

Jason Segal

The Pulse Check

CAR-T Cell Therapies back on the menu with $7.8 billion acquisition

Feb 24, 2026

•

6 min read

CAR-T Cell Therapies back on the menu with $7.8 billion acquisition

Jason Segal

The Pulse Check

Sprinting to the starting line: The Rhythm Biosciences (ASX: RHY) Story

Feb 23, 2026

•

13 min read

Sprinting to the starting line: The Rhythm Biosciences (ASX: RHY) Story

Jason Segal

The Pulse Check

Feb 20, 2026

•

10 min read

The Three-Day Market Update

Jason Segal

The Pulse Check

The Price of Buying Time: The Adherium (ASX: ADR) Story

Feb 17, 2026

•

12 min read

The Price of Buying Time: The Adherium (ASX: ADR) Story

Jason Segal

Clarity Pharmaceuticals (ASX: CU6)

Feb 16, 2026

•

13 min read

The Path to Blue-Chip: The Clarity Pharmaceuticals (ASX: CU6) Story

Jason Segal

The Pulse Check

Feb 13, 2026

•

10 min read

Why do stocks fall on good news

Jason Segal

The Pulse Check

The Greatest Wealth Creator in Australian Biotech: The CSL Story

Feb 12, 2026

•

11 min read

The Greatest Wealth Creator in Australian Biotech: The CSL Story

Jason Segal

The Pulse Check

Why I'm not catching the CSL falling knife

Feb 11, 2026

•

8 min read

Why I'm not catching the CSL falling knife

Jason Segal

The Pulse Check

A 20-Year Overnight Success: The Memphasys (ASX: MEM) Story.

Feb 10, 2026

•

12 min read

A 20-Year Overnight Success: The Memphasys (ASX: MEM) Story.

Jason Segal

The Pulse Check

Why fundamental analysis doesn't work for Biotech Stocks

Feb 9, 2026

•

8 min read

Why fundamental analysis doesn't work for Biotech Stocks

Jason Segal